Clinical Trial Update: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of RO6889450 (ralmitaront) versus placebo in acute exacerbations of schizophrenia or schizoaffective disorder; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• RO6889450 (ralmitaront) (ralmitaront)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED | Results posted: 2023-10-10